1-7 of 7
Walter M. Gregory
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment

Claudia Tulotta, Diane V. Lefley, Katy Freeman, Walter M. Gregory, Andrew M. Hanby, Paul R. Heath, Faith Nutter, J. Mark Wilkinson, Amy R. Spicer-Hadlington, Xinming Liu, Steven M.J. Bradbury, Lisa Hambley, Victoria Cookson, Gloria Allocca, Marianna Kruithof de Julio, Robert E. Coleman, Janet E. Brown, Ingunn Holen, Penelope D. Ottewell
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (9): 2769–2782.
https://doi.org/10.1158/1078-0432.CCR-18-2202
Published: 01 May 2019
View article titled, Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment
Open the PDF for Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment in another window
Includes: Supplementary data
Journal Articles

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma

Charlotte Pawlyn, Martin F. Kaiser, Christoph Heuck, Lorenzo Melchor, Christopher P. Wardell, Alex Murison, Shweta S. Chavan, David C. Johnson, Dil B. Begum, Nasrin M. Dahir, Paula Z. Proszek, David A. Cairns, Eileen M. Boyle, John R. Jones, Gordon Cook, Mark T. Drayson, Roger G. Owen, Walter M. Gregory, Graham H. Jackson, Bart Barlogie, Faith E. Davies, Brian A. Walker, Gareth J. Morgan
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (23): 5783–5794.
https://doi.org/10.1158/1078-0432.CCR-15-1790
Published: 30 November 2016
View article titled, The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
Open the PDF for The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma in another window
Includes: Supplementary data
Journal Articles

Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Susan E. Bell, Alexander J. Szubert, Gordon Cook, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (21): 6030–6038.
https://doi.org/10.1158/1078-0432.CCR-12-3211
Published: 31 October 2013
View article titled, Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
Open the PDF for Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment in another window
Journal Articles

Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

Kevin D. Boyd, Fiona M. Ross, Brian A. Walker, Christopher P. Wardell, William J. Tapper, Laura Chiecchio, GianPaolo Dagrada, Zoe J. Konn, Walter M. Gregory, Graham H. Jackson, J. Anthony Child, Faith E. Davies, Gareth J. Morgan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7776–7784.
https://doi.org/10.1158/1078-0432.CCR-11-1791
Published: 18 December 2011
View article titled, Mapping of Chromosome 1p Deletions in Myeloma Identifies <em>FAM46C</em> at 1p12 and <em>CDKN2C</em> at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
Open the PDF for Mapping of Chromosome 1p Deletions in Myeloma Identifies <em>FAM46C</em> at 1p12 and <em>CDKN2C</em> at 1p32.3 as Being Genes in Regions Associated with Adverse Survival in another window
Includes: Supplementary data
Journal Articles

A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment

Ping Wu, Brian A. Walker, Daniel Brewer, Walter M. Gregory, John Ashcroft, Fiona M. Ross, Graham H. Jackson, Anthony J. Child, Faith E. Davies, Gareth J. Morgan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (19): 6347–6355.
https://doi.org/10.1158/1078-0432.CCR-11-0994
Published: 02 October 2011
View article titled, A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment
Open the PDF for A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment in another window
Includes: Supplementary data
Journal Articles

Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome

Nicholas J. Dickens, Brian A. Walker, Paola E. Leone, David C. Johnson, José L. Brito, Athanasia Zeisig, Matthew W. Jenner, Kevin D. Boyd, David Gonzalez, Walter M. Gregory, Fiona M. Ross, Faith E. Davies, Gareth J. Morgan
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1856–1864.
https://doi.org/10.1158/1078-0432.CCR-09-2831
Published: 14 March 2010
View article titled, Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome
Open the PDF for Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome in another window
Includes: Supplementary data
Journal Articles

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer

Fiona M. Platt, Carolyn D. Hurst, Claire F. Taylor, Walter M. Gregory, Patricia Harnden, Margaret A. Knowles
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6008–6017.
https://doi.org/10.1158/1078-0432.CCR-09-0898
Published: 30 September 2009
View article titled, Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
Open the PDF for Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer in another window
Includes: Supplementary data